VIVO - Meridian Bioscience Non-GAAP EPS of $0.66 beats by $0.19 revenue of $111.23M beats by $11.68M
Meridian Bioscience press release (NASDAQ:VIVO): FQ2 Non-GAAP EPS of $0.66 beats by $0.19. Revenue of $111.23M (+30.5% Y/Y) beats by $11.68M. The company is raising FY2022 outlook: Net revenue: $330M to $345M vs. consensus of $337.62M; Adjusted Operating Margin: 22.5% to 23.5%; Adjusted diluted EPS: $1.30 to $1.40 vs. consensus of $1.38.
For further details see:
Meridian Bioscience Non-GAAP EPS of $0.66 beats by $0.19, revenue of $111.23M beats by $11.68M